Sequencing of therapy and follow-up in patients with metastatic castrate resistant prostate cancer
Authors:
J. Katolická
Published in:
Urol List 2012; 10(4): 41-44
Overview
Two studies – TAX 327 and SWOG 9916 – have demonstrated for the first time the benefit in survival in patients with metastatic castrate resistant prostate cancer (mCRPC) treated with chemotherapy based on docetaxel, which is currently considered the standard agent for the first line treatment. III phase studies testing cabazitaxel, abirateron, sipuleucel-T, alpharadin, and enzalutamid as the second line treatment of castrate resistant prostate cancer have recently demonstrated benefit of prolonged survival while maintaining good quality of life and tolerable toxicity. More clinical studies and clinical experience are required to further reveal the correct sequencing of the individual agents.
Key words:
castrate resistant prostate cancer - docetaxel - cabazitaxel - abirateron - sipuleucel T - alpharadin - enzalutamid
Sources
1. Ansari J, Hussain SA, Alhasso A et al. Role of second-line systemictreatment post-docetaxel in metastatic castrate resistant prostate cancer – current strategies and future directions. Anticancer Agents Med Chem 2011; 11(3): 296–306.
2. De Bono JS, Oudard S, Ozguroglu M et al. Pred-nisone plus cabazitaxel or mitoxantrone for meta-static castration-resistant prostate cancer (mCRPC) progresing after docetaxel treatment: a rando-mized open-label trial. Lancet 2010; 376(9747): 1147–1154.
3. deBonno JS, Logothetis CJ, Molina A et al. Abiraterone and Oncreased Survival in Metastatic Prostate Cancer. N Engl J Med 2011; 364(21): 1995–2005.
4. Ansari J, Husain SA, Zarkar A et al. Docetaxel and prednisolone chemotherapy for metastatic hormone refraktory prostate canecr as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol Rep 2008; 20(4): 891–896.
5. Eymard JC, Oudard S, Gravis G et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 2010; 106(7): 974–978.
6. Cha E, Fong L. Imunoterapie karcinomu pros-taty: biologické a léčebné aspekty. JCO 2011; 3: 308–315.
7. Zampino MG, Verri E, Locatelli M et al. Vinorelbine--based Chemotherapy in Hormone-refractory Prostate Cancer. Anticancer Res 2006; 26(3B): 2375–2380.
8. Rodriguez GA, Sepulveda J, Cortijo A et al. Oral vinorelbine as a fixed-weekly schedule in taxanes-refractory advanced HRPC: A single institution experience. J Clin Oncol 2009; abstr 16084.
9. Parker C, Nilsson S et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-233 chloride in castration-resistant prostate cancer (CRCP) patients with bone metastases (ALSYMPCA), ASCO 2012.
Labels
Paediatric urologist UrologyArticle was published in
Urological Journal
2012 Issue 4
Most read in this issue
- Adverse events of hormone replacement testosterone therapy
- Testicular adenomatoid tumor – diagnosis and operating procedures
- Vaporizace prostaty pomocí zeleného laseru (GreenLight laser) – zkušenost z jednoho centra po provedení více než 1 000 výkonů
- Development of surgical retrieval a men's sperm with azoospemia